(CercleFinance.com) – DBV Technologies fell 3% after the biopharmaceutical company announced cash and cash equivalents of $212.7 million as of September 30, 2022, from $77.3 million. million as of December 31, 2021.
This net increase over nine months is mainly made up of the private placement carried out in June for 180.6 million, partially offset by the net consumption of cash from operating activities of 58.2 million dollars.
Over the first nine months of the year, DBV suffered a net loss per share of $0.79, but with operating income more than doubled to 6.1 million, against 2.8 million over the same period in 2021.